Maria
Vieito Amor
Eli Lilly and Company
Indianapolis, EE. UU.Publications in collaboration with researchers from Eli Lilly and Company (1)
2021
-
First-In-Human Phase I Study of a Next-Generation, Oral, TGFb Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Clinical Cancer Research, Vol. 27, Núm. 24, pp. 6666-6676